Table 1.
Demographic data of all 105 subjects
| Pathological diagnosis | All | AGD | PSP | AD | PART † | PART without other degenerative diseases | CBD | GGT | DNTC | Pick’s disease | FTLD‐MAPT (P301L) | Postencephalitic parkinsonism | Myotonic dystrophy | MSA | FTLD‐TDP | ALS‐TDP | FTLD‐FUS | Huntington’s disease | DRPLA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of cases (N) | 105 | 26 | 10 | 20 | 18 | (5) | 7 | 2 | 5 | 3 | 1 | 1 | 4 | 6 | 3 | 4 | 3 | 1 | 4 |
| Male/female (N) | 60/45 | 13/13 | 8/2 | 9/11 | 14/4 | (5/0) | 5/2 | 0/2 | 2/3 | 1/2 | 1/0 | 1/0 | 2/2 | 3/3 | 2/1 | 4/0 | 2/1 | 0/1 | 2/2 |
| Age at death (y) (mean ± SD) | 70.4 ± 11.8 | 77.0 ± 11.9 | 70.0 ± 7.9 | 80.9 ± 8.7 | 66.3 ± 9.7 | (69.8 ± 4.4) | 62.3 ± 12.1 | 68.0 ± 12.7 | 60.6 ± 13.5 | 74.0 ± 9.0 | 60 | 72 | 58.0 ± 7.1 | 63.7 ± 7.5 | 72.7 ± 9.5 | 65.3 ± 10.2 | 64.5 ± 3.5 | 59 | 51.0 ± 10.2 |
| (range) | 42‐95 | 61‐94 | 61‐84 | 63‐95 | 52‐82 | (63‐74) | 45‐85 | 59‐77 | 48‐75 | 65‐83 | ‐ | ‐ | 50‐67 | 58‐76 | 63‐82 | 66‐77 | 45‐62 | ‐ | 42‐65 |
| Brain weight (g, mean ± SD) | 1154 ± 224.4 | 1180.5 ± 173.9 | 1236.7 ± 246.8 | 1072.0 ± 188.8 | 1159.0 ± 301.3 | (1367.4 ± 152.6) | 1238.6 ± 150.2 | 1120.0 ± 198.0 | 946.7 ± 126.6 | 863.3 ± 225.9 | 970 | 1210 | 1117.0 ± 115.9 | 1178.0 ± 192.0 | 933.0 ± 198.0 | 1438.0 ± 92.3 | 1100.0 ± 203.0 | 610 | 1017.5 ± 263.2 |
| Braak stage (6), median (25th‐75th percentiles) | 2 (1‐4) | 2 (1‐2) | 1 (1‐2) | 5 (5‐6) | 1 (1‐1.5) | 2 (1‐2) | 2 (1‐2.5) | 1.5 (0.25‐0.75) | 6 (6‐6) | 2 (1‐2) | 1 (1‐1) | 5 (0‐0) | 3 (2‐4) | 2 (1.25‐3.5) | 1 (0.5‐1) | 2.5 (1‐4) | 0 (0‐0) | 1 (1‐1) | 0 (0‐0.5) |
| Thal phase (69), median (25th‐75th percentiles) | 0 (0‐3) | 1 (0‐3) | 1 (0‐1.75) | 5 (4‐5) | 0 (0‐0.5) | 0 (0.0) | 0 (0‐1) | 0.5 (0.25‐0.75) | 0 (0‐0) | 1 (0.5‐2.5) | 0 (0‐0) | 4 (0‐0) | 0 (0‐0) | 0.5 (0‐1.75) | 1 (0.5‐1) | 0 (0‐0.25) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) |
| AGD stage (63), median (25th‐75th percentiles) | 0 (0‐1) | 2 (1‐2) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 1 (1‐2.5) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) | 0 (0‐0) |
| Cases having LBD [N, (%)] | 25 (23.8) | 4 (15.4) | 2 (20.0) | 11 (55.0) | 1 (5.6) | 0 (0.0) | 1 (14.3) | 1 (50.0) | 4 (80.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cases having TDP‐43 pathology [N, (%)] | 33 (31.4) | 6 (23.1) | 4 (40.0) | 13 (65.0) | 6 (33.3) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 1 (20.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (100.0) | 4 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Abbreviations: AD = Alzheimer’s disease; AGD = argyrophilic grain disease; CBD = corticobasal degeneration; DNTC = diffuse neurofibrillary tangles with calcification; DRPLA = dentatorubral‐pallidoluysian atrophy; FTLD‐FUS = frontotemporal lobar degeneration with FUS‐positive inclusions; FTLD‐MAPT = frontotemporal lobar degeneration with tau gene mutation; FTLD‐TDP = frontotemporal lobar degeneration with TDP‐43‐positive inclusions; GGT = globular glial tauopathy; LBD = Lewy body disease; MSA = multiple system atrophy; N = number; NFT = neurofibrillary tangles; PART = primary age‐related tauopathy; PSP = progressive supranuclear palsy; SD = standard deviation.
The PART group is composed of five PART cases without any other degenerative diseases and 13 PART cases with some non‐tauopathy (e.g., FTLD‐TDP, ALS‐TDP, MSA, DRPLA and Huntington’s disease). Detailed demographic data of the PART group are shown in Supporting File S1.